Prospectus 5/29/2020 | NWBO Message Board Posts

Northwest Biotherapeutics Inc.

  NWBO website

  •  Registered Members of Investor Village:
    Please make sure you are signed in to your Investor Village account to enjoy the full benefits of our service and avoid the MediaPass paywall. If the MediaPass offer page is blocking you, click the light blue "No thanks, take me back" link on the middle right side of the form to get to our home page where you can sign in by entering your Investor Village User Name and Password. 

     MediaPass subscribers: Please make sure you are logged in to your MediaPass subscription to bypass the paywall. You can do this by clicking the light blue "Already have a MediaPass account? Login here" link on the middle left side of the subscription offer form and then entering the email address and password you used when you first signed up with MediaPass.  

    For assistance call 888-222-7309 or email

NWBO   /  Message Board  /  Read Message



Rec'd By
Authored By
Minimum Recs
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  13985 of 13994  at  6/28/2020 3:09:41 PM  by


The following message was updated on 6/28/2020 3:17:18 PM.

 In response to msg 13947 by  Hodag
view thread

Re: Prospectus 5/29/2020

Enough resources have already been wasted on them. As for neoantigen based vaccines, they are being given with anti-PD(L)-1 agents, but based on the data [1] I think they will show much better activity in patients who have had SOC and test positive for ctDNA after (both BNTX/RHBBY & GRTS are going to be doing this) [2].

In those with advanced disease cell based therapies are going to be a much better option as this approach enables rapid innovation, can build on versions that have been established, minimises systemic toxicities observed with many immunotherapies, may reduce overall costs and should greatly improve the antitumour activity as they can be 'tailored' to combat the complexity of different TMEs.

An example would be AUTL's AUTO7. This CAR-T consists of six transgenes. They are: 1) an anti-PSMA CAR based on a novel humanised binder; 2) a safety switch; 3) dominant negative TGFbRII to induce TGF-b resistance; 4) truncated SHP2 to stop PD-1/CTLA-4/TIGIT/BTLA/2B4 pathway inhibition; 5) a constitutively active cytokine signal (in addition to the 4-1BB co-stim) to improve proliferation and persistence, and finally 6) IL-12 to modulate the suppressive TME by local secretion. Future versions could have a number of other improvements, like this [3].


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0     Views: 57
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Msg # Subject Author Recs Date Posted
13986 Re: Prospectus 5/29/2020 Hodag 0 6/28/2020 4:24:50 PM

About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 All rights reserved. User Agreement
Financial Market Data provided by